| Symbol | BFRIW |
|---|---|
| Name | BIOFRONTERA INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 660 MAIN STREET, WOBURN, Massachusetts, 01801, United States |
| Telephone | +1 781 - 245-1325 |
| Fax | — |
| — | |
| Website | https://www.biofrontera-us.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | Biofrontera Inc is a biopharmaceutical company specializing in the commercialization of pharmaceutical products for the treatment of dermatological conditions, diseases caused by exposure to sunlight that result in sun damage to the skin. Its licensed products focus on the treatment of actinic keratoses, which are skin lesions that can sometimes lead to skin cancer. It also markets a topical antibiotic for the treatment of impetigo, a bacterial skin infection. Additional info from NASDAQ: |
(30% Negative) BIOFRONTERA INC. (BFRIW) Reports Q1 2026 Financial Results
Read moreBiofrontera Inc. Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
Read moreBiofrontera Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call on March 19, 2026
Read more(90% Positive) BIOFRONTERA INC. (BFRI) Provides Update on indication for Ameluz®
Read moreBiofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for moderate to severe Acne Vulgaris
Read moreDirector Weber Kevin Daniel 🟢 acquired 20.0K shares (1 derivative) of Biofrontera Inc. (BFRI) at $0.90 Transaction Date: Mar 04, 2026 | Filing ID: 009259
Read moreDirector Luebbert Hermann 🟡 adjusted position in 250.0K shares (3 derivative) of Biofrontera Inc. (BFRI) at $0.90 Transaction Date: Mar 04, 2026 | Filing ID: 009257
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07053852 | Activation of Ameluz With BBL HEROic for the Treatment of Actinic Keratoses and… | Phase1 | Actinic Keratoses | Completed | 2025-06-27 | 2025-12-29 | ClinicalTrials.gov |
| NCT06577311 | Evaluating the Use of Photodynamic Therapy to Treat Facial Cutaneous Squamous C… | Phase2 | Cutaneous Squamous Cell Carcinoma | Recruiting | 2024-08-14 | 2025-08-01 | ClinicalTrials.gov |
| NCT06027619 | Short Contact Protocols to Reduce Pain During 10% ALA Gel Red-light Photodynami… | Phase2 | Actinic Keratosis | Completed | 2023-10-02 | 2024-07-08 | ClinicalTrials.gov |
| NCT05662202 | Study to Evaluate the Safety, Tolerability and Efficacy of BF-200 ALA (Ameluz®)… | Phase3 | Actinic Keratoses | Active_Not_Recruiting | 2022-12-12 | 2026-06-01 | ClinicalTrials.gov |
| NCT05080764 | Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoL… | Phase2 | Acne Vulgaris | Active_Not_Recruiting | 2021-12-10 | 2026-01-01 | ClinicalTrials.gov |
| NCT05060237 | Study to Evaluate Safety and Tolerability of BF-200 ALA (Ameluz®) for Photodyna… | Phase1 | Actinic Keratosis | Completed | 2021-12-01 | 2023-04-20 | ClinicalTrials.gov |
| NCT04319159 | Study to Evaluate the Safety of BF-200 ALA (Ameluz®) for Photodynamic Therapy (… | Phase1 | Actinic Keratoses | Completed | 2020-03-05 | 2020-10-07 | ClinicalTrials.gov |
| NCT03573401 | Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoL… | Phase3 | Superficial Basal Cell Carcinoma | Active_Not_Recruiting | 2018-09-25 | 2029-02-01 | ClinicalTrials.gov |
| NCT02144077 | Safety and Efficacy Study for the Treatment of Non-Aggressive Basal Cell Carcin… | Phase3 | Basal Cell Carcinoma (BCC) | Completed | 2014-01-28 | 2020-09-09 | ClinicalTrials.gov |
| NCT01966120 | Safety and Efficacy Study for the Field-directed Treatment of Actinic Keratosis… | Phase3 | Actinic Keratosis | Completed | 2013-10-01 | 2015-04-01 | ClinicalTrials.gov |
| NCT02799069 | Evaluation of Safety and Efficacy of BF-200 ALA for the Treatment of Actinic Ke… | Phase3 | Actinic Keratosis | Completed | 2008-04-01 | 2009-08-01 | ClinicalTrials.gov |
| NCT02799082 | Evaluation of Efficacy and Safety of BF-200 ALA Used With Photodynamic Therapy … | Phase3 | Actinic Keratosis | Completed | 2007-12-01 | 2008-10-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Red light illumination | DEVICE | Phase PHASE2 | Actinic Keratosis | COMPLETED | NCT06027619 |
| Topical aminolevulinate (10% ALA gel) | DRUG | Phase PHASE2 | Actinic Keratosis | COMPLETED | NCT06027619 |